Intelligence Feed event · Policy · 2026-08-31

    HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso

    Question

    HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso

    Direct answer

    HUTCHMED announced that its Phase III SANOVO registration trial achieved its primary endpoint of progression-free survival in treatment-naïve patients suffering from MET-overexpressing, EGFR-mutated non-small cell lung cancer in China. The regimen evaluates the combination of HUTCHMED's ORPATHYS (savolitinib) and AstraZeneca's TAGRISSO (osimertinib). The positive outcome sets the foundation for supplemental regulatory filings in China's domestic oncology market.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-31
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso”, revision 1, evidence through 2026-08-31. https://marketontology.com/market-events/2026-08-31/hutchmed-and-astrazeneca-report-positive-phase-iii-trial-for-orpathys-plus-tagri-6edd67

    POLICY
    HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso
    HUTCHMED announced that its Phase III SANOVO registration trial achieved its primary endpoint of progression-free survival in treatment-naïve patients suffering from MET-overexpressing, EGFR-mutated non-small cell lung cancer in China. The regimen evaluates the combination of HUTCHMED's ORPATHYS (savolitinib) and AstraZeneca's TAGRISSO (osimertinib). The positive outcome sets the foundation for supplemental regulatory filings in China's domestic oncology market.
    HCMAZN
    Impact
    71
    AUG 31
    SIG
    92%
    HCMAZN
    HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso
    HUTCHMED announced that its Phase III SANOVO registration trial achieved its primary endpoint of progression-free survival in treatment-naïve patients suffering from MET-overexpressing, EGFR-mutated non-small cell lung cancer in China. The regimen evaluates the combination of HUTCHMED's ORPATHYS (savolitinib) and AstraZeneca's TAGRISSO (osimertinib). The positive outcome sets the foundation for supplemental regulatory filings in China's domestic oncology market.
    → Positive Phase III oncology data triggers expanded regulatory approval filings in mainland China, expanding royalty streams and commercial revenue potential for co-development partners.
    Impact
    HUTCHMED announced that its Phase III SANOVO registration trial achieved its primary endpoint of progression-free survival in treatment-naïve patients suffering from MET-overexpressing, EGFR-mutated non-small cell lung cancer in China. The regimen evaluates the combination of HUTCHMED's ORPATHYS (savolitinib) and AstraZeneca's TAGRISSO (osimertinib). The positive outcome sets the foundation for supplemental regulatory filings in China's domestic oncology market.
    Affected
    HCMAZN
    Transmission
    Positive Phase III oncology data triggers expanded regulatory approval filings in mainland China, expanding royalty streams and commercial revenue potential for co-development partners.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMcommercial drug label expansion in ChinaUp1-5dPositive Phase III SANOVO trial met PFS primary endpoint in China.
    AZNcombination therapy franchise expansionUp1-4wTAGRISSO combination achieved statistically significant progression-free survival benefit.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed12.12 2026-08-31-1.73%+14.52%+16.75%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month